Jay Yang

3.3k total citations
103 papers, 1.3k citations indexed

About

Jay Yang is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Jay Yang has authored 103 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 46 papers in Hematology and 20 papers in Genetics. Recurrent topics in Jay Yang's work include Acute Myeloid Leukemia Research (35 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). Jay Yang is often cited by papers focused on Acute Myeloid Leukemia Research (35 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). Jay Yang collaborates with scholars based in United States, Canada and France. Jay Yang's co-authors include Grant W. Brown, Ian D. Hickson, Csanád Z. Bachrati, Jeffrey W. Taub, Holly Edwards, Yubin Ge, Yongwei Su, Maik Hüttemann, Rong Guo and Jenna L. Carter and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jay Yang

92 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay Yang United States 18 810 318 281 205 156 103 1.3k
Olga Goloubeva United States 16 755 0.9× 264 0.8× 502 1.8× 239 1.2× 186 1.2× 27 1.3k
Shripad Sinari United States 13 407 0.5× 241 0.8× 216 0.8× 150 0.7× 210 1.3× 22 891
Giovanni Roti Italy 23 823 1.0× 575 1.8× 312 1.1× 76 0.4× 159 1.0× 57 1.5k
Susan Korenchuk United States 13 896 1.1× 165 0.5× 348 1.2× 462 2.3× 204 1.3× 18 1.4k
Ehsan Malek United States 15 744 0.9× 397 1.2× 538 1.9× 95 0.5× 261 1.7× 113 1.3k
Benedetta Peruzzi Italy 18 612 0.8× 122 0.4× 233 0.8× 151 0.7× 186 1.2× 38 1.2k
David Cervi United States 13 554 0.7× 281 0.9× 377 1.3× 104 0.5× 226 1.4× 21 948
Ivy Fearen United States 9 722 0.9× 201 0.6× 288 1.0× 116 0.6× 101 0.6× 11 926
Ricardo Parrondo United States 15 374 0.5× 196 0.6× 255 0.9× 92 0.4× 100 0.6× 75 698
Satoki Nakamura Japan 21 606 0.7× 243 0.8× 216 0.8× 57 0.3× 102 0.7× 68 1.0k

Countries citing papers authored by Jay Yang

Since Specialization
Citations

This map shows the geographic impact of Jay Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Yang more than expected).

Fields of papers citing papers by Jay Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Yang. The network helps show where Jay Yang may publish in the future.

Co-authorship network of co-authors of Jay Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Yang. A scholar is included among the top collaborators of Jay Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Yang. Jay Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carter, Jenna L., Yongwei Su, Jianlei Zhao, et al.. (2025). ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress. Journal of Experimental & Clinical Cancer Research. 44(1). 10–10.
2.
Cortes, Jörge E., Gail J. Roboz, Maria R. Baer, et al.. (2025). Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of Hematology & Oncology. 18(1). 7–7. 7 indexed citations
3.
Aly, Mai, Tariq Kewan, Waled Bahaj, et al.. (2025). Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia: A Real-World Experience. Cancers. 17(6). 1020–1020. 2 indexed citations
4.
Yang, Jay, et al.. (2025). Seasonality of the estrus cycle in laboratory mice under constant conditions. Laboratory Animals. 59(4). 450–463.
5.
6.
Fathi, Amir T., Aleksandra Filipović, Dale Schaar, et al.. (2024). A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS. Blood. 144(Supplement 1). 1499–1499. 3 indexed citations
7.
Atallah, Ehab, Michael S. Broder, Onyee Chan, et al.. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. 144(Supplement 1). 5052–5052.
8.
Wang, Eunice S., Jörge E. Cortes, Justin M. Watts, et al.. (2024). Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Blood. 144(Supplement 1). 1514–1514.
9.
Uddin, Md. Hafiz, Amro Aboukameel, Husain Yar Khan, et al.. (2024). Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2768–2768. 2 indexed citations
10.
Sharma, Aditi, Jay Yang, & Vijendra K. Singh. (2023). Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States. Annals of Hematology. 102(5). 1053–1062. 4 indexed citations
11.
12.
Gong, Yan, Yohei Tomita, Matthew L. Edin, et al.. (2022). Cytochrome P450 oxidase 2J inhibition suppresses choroidal neovascularization in mice. Metabolism. 134. 155266–155266. 7 indexed citations
13.
Carter, Jenna L., Jay Yang, Hasini A. Kalpage, et al.. (2020). Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy. 5(1). 288–288. 143 indexed citations
14.
Gounder, Mrinal M., Priscilla Merriam, Ravin Ratan, et al.. (2020). Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer. 127(8). 1311–1317. 12 indexed citations
15.
Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations
16.
17.
Grote, David, Simon Girard, Jalila Chagraoui, et al.. (2013). The Bmi1-interacting protein E4f1 is vital for hematopoietic stem/progenitor cell function. Experimental Hematology. 41(8). S15–S15. 1 indexed citations
18.
Yang, Jay, Lara O’Donnell, Daniel Durocher, & Grant W. Brown. (2012). RMI1 Promotes DNA Replication Fork Progression and Recovery from Replication Fork Stress. Molecular and Cellular Biology. 32(15). 3054–3064. 27 indexed citations
19.
Yang, Jay, Csanád Z. Bachrati, Ian D. Hickson, & Grant W. Brown. (2012). BLM and RMI1 Alleviate RPA Inhibition of TopoIIIα Decatenase Activity. PLoS ONE. 7(7). e41208–e41208. 6 indexed citations
20.
Xu, Dongyi, Rong Guo, Alexandra Sobeck, et al.. (2008). RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability. Genes & Development. 22(20). 2843–2855. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga Goloubeva Breakdown of academic impact, for papers by Shripad Sinari Breakdown of academic impact, for papers by Giovanni Roti Breakdown of academic impact, for papers by Susan Korenchuk Breakdown of academic impact, for papers by Ehsan Malek Breakdown of academic impact, for papers by Benedetta Peruzzi Breakdown of academic impact, for papers by David Cervi Breakdown of academic impact, for papers by Ivy Fearen Breakdown of academic impact, for papers by Ricardo Parrondo Breakdown of academic impact, for papers by Satoki Nakamura
Rankless by CCL
2026